New pulmonary hypertension drug F230 enters first human safety tests
NCT ID NCT06899815
First seen Mar 12, 2026 · Last updated May 13, 2026 · Updated 9 times
Summary
This early-stage study tests a new medicine called F230 in 136 healthy adults to see if it is safe and how the body processes it. The drug is designed to treat pulmonary hypertension, a serious lung condition. Researchers will also check if food changes how the drug works. No direct treatment benefit is expected for participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGHubei, Wuhan, 430022, China
Conditions
Explore the condition pages connected to this study.